Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Chubb
Queensland Health
Johnson and Johnson
Dow
Covington
Chinese Patent Office
Baxter
Harvard Business School

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,319,913

« Back to Dashboard

Which drugs does patent 6,319,913 protect, and when does it expire?

Patent 6,319,913 protects FORTESTA and is included in one NDA.

This patent has nineteen patent family members in sixteen countries.
Summary for Patent: 6,319,913
Title: Penetration enhancing and irritation reducing systems
Abstract:This invention lies in the technology of transdermal and topical drug delivery. In particular, the present invention relates to enhancement of the penetration of transdermally or topically applied drugs and with the reduction of skin irritation that often accompanies transdermal and topical drug delivery.
Inventor(s): Mak; Vivien H. W. (Menlo Park, CA), Grayson; Stephen (San Rafael, CA)
Assignee: Cellegy Pharmaceuticals, Inc. (South San Francisco, CA)
Application Number:09/189,090
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 6,319,913

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Endo Pharms FORTESTA testosterone GEL, METERED;TRANSDERMAL 021463-001 Dec 29, 2010 AB RX Yes Yes ➤ Subscribe ➤ Subscribe TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,319,913

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,579,865 Penetration enhancing and irritation reducing systems ➤ Subscribe
7,157,097 Penetration enhancing and irritation reducing systems ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,319,913

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal 1510213 ➤ Subscribe
New Zealand 504423 ➤ Subscribe
Norway 20002422 ➤ Subscribe
Japan 2005047932 ➤ Subscribe
Japan 4139860 ➤ Subscribe
Japan 2001522804 ➤ Subscribe
Israel 136042 ➤ Subscribe
Hong Kong 1074788 ➤ Subscribe
Spain 2318233 ➤ Subscribe
European Patent Office 1510213 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Deloitte
Harvard Business School
Cerilliant
Fish and Richardson
Colorcon
Boehringer Ingelheim
Cipla
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot